

CONFIDENTIAL



NOTIFICATION PURSUANT TO

18 V.S.A. § 4637(b)

Subject: Notification Pursuant to 18 V.S.A. § 4637(b)

To the Office of the Attorney General of Vermont:

Genentech USA, Inc. hereby notifies the Attorney General of Vermont of the following new prescription drug, pursuant to 18 V.S.A. § 4637(b):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC (Wholesale Acquisition Cost) (As of the Date of Commercial Availability)
Xolair 75mg Prefilled Syringe	50242-0214-01	December 11, 2018	\$542.33
Xolair 150mg Prefilled Syringe	50242-0215-01	December 11, 2018	\$1084.66

Sincerely,

Maria Aquilina
Director, Government Programs
Genentech USA, Inc.